Want to see IN:METROPOLIS full AI Analyst Report?
METROPOLIS Stock Chart & Stats
₹1929.70
-₹8.50(-0.42%)
At close: 4:00 PM EST
₹1929.70
-₹8.50(-0.42%)
Day’s Range― - ―
52-Week Range₹413.00 - ₹608.95
Previous CloseN/A
Volume139.28K
Average Volume (3M)3.90K
Market Cap
₹115.43B
Enterprise Value₹90.16K
Total Cash (Recent Filing)₹2.03B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)57.2
Beta0.63
Next Earnings
Nov 10, 2026EPS Estimate
3.43Next Dividend Ex-DateN/A
Dividend Yield0.36%
Share Statistics
EPS (TTM)9.73
Shares Outstanding207,368,870
10 Day Avg. Volume4,604
30 Day Avg. Volume3,901
Financial Highlights & Ratios
PEG Ratio1.54
Price to Book (P/B)5.93
Price to Sales (P/S)5.45
P/FCF Ratio30.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.38
Revenue Forecast (FY)₹19.02B
Bulls Say, Bears Say
Bulls Say
Revenue Re-accelerationA stronger top-line trajectory indicates improving demand for diagnostic services and supports operating scale. Sustained volume growth across routine and specialized testing can reinforce Metropolis's market reach over the next several quarters.
Strong Cash GenerationReliable positive cash generation gives the company internal funding for laboratory capacity, collection-network expansion and technology investment. The FY2026 improvement also strengthens resilience without relying heavily on external financing.
Conservative LeverageModest leverage and steadily growing equity provide financial flexibility for investment or acquisitions while limiting balance-sheet risk. This capitalization should help Metropolis withstand demand or cost volatility across the diagnostic cycle.
Bears Say
Profitability Below Prior PeakEarnings have not kept pace with the expanded revenue base, indicating that cost control, pricing or service mix may be limiting operating leverage. Persistent margin variability could constrain the durability of future profit growth.
Volatile Cash ConversionAlthough total cash generation is positive, inconsistent conversion from reported earnings can make funding capacity less predictable. Working-capital swings or collection timing may reduce the reliability of reinvestment and debt-servicing planning.
FY2026 Debt IncreaseThe recent debt increase introduces a need to monitor whether borrowing supports productive expansion or reflects rising funding requirements. Even with low leverage today, continued increases could gradually reduce financial flexibility.
Metropolis Healthcare Ltd. News
METROPOLIS FAQ
What was Metropolis Healthcare Ltd.’s price range in the past 12 months?
Metropolis Healthcare Ltd. lowest stock price was ₹413.00 and its highest was ₹608.95 in the past 12 months.
What is Metropolis Healthcare Ltd.’s market cap?
Metropolis Healthcare Ltd.’s market cap is ₹115.43B.
When is Metropolis Healthcare Ltd.’s upcoming earnings report date?
Metropolis Healthcare Ltd.’s upcoming earnings report date is Nov 10, 2026 which is in 77 days.
How were Metropolis Healthcare Ltd.’s earnings last quarter?
Metropolis Healthcare Ltd. released its earnings results on Aug 04, 2026. The company reported ₹2.7 earnings per share for the quarter, beating the consensus estimate of ₹2.677 by ₹0.023.
Is Metropolis Healthcare Ltd. overvalued?
According to Wall Street analysts Metropolis Healthcare Ltd.’s price is currently Overvalued.
Does Metropolis Healthcare Ltd. pay dividends?
Metropolis Healthcare Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.36%. See more information on Metropolis Healthcare Ltd. dividends here
What is Metropolis Healthcare Ltd.’s EPS estimate?
Metropolis Healthcare Ltd.’s EPS estimate is 3.43.
How many shares outstanding does Metropolis Healthcare Ltd. have?
Metropolis Healthcare Ltd. has 207,368,870 shares outstanding.
What happened to Metropolis Healthcare Ltd.’s price movement after its last earnings report?
Metropolis Healthcare Ltd. reported an EPS of ₹2.7 in its last earnings report, beating expectations of ₹2.677. Following the earnings report the stock price went down -1.367%.
Which hedge fund is a major shareholder of Metropolis Healthcare Ltd.?
Currently, no hedge funds are holding shares in IN:METROPOLIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Metropolis Healthcare Ltd.
Metropolis Healthcare Limited functions as a prominent diagnostic service provider throughout India. The company delivers a comprehensive array of clinical laboratory testing, specialized diagnostic profiles, and associated support services. Its capabilities span diverse medical fields, encompassing oncology, neurology, gynecology, and nephrology. Furthermore, Metropolis offers a variety of health check-up packages specifically tailored for different demographic groups, including men, women, senior citizens, youth, and corporate clients. These tests are vital for disease prediction, early identification, diagnostic screening, confirmation, and continuous monitoring. Beyond its core diagnostic offerings, the company also extends its expertise to corporate wellness programs, hospital laboratory management solutions, and clinical research. As of March 31, 2022, Metropolis had established an extensive network comprising 171 clinical laboratories, 9,000 sample collection points, and 704 assisted referral centers. Founded in 1980, the company's corporate headquarters are situated in Mumbai, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―